Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early responseFara Brasó‐Maristany, Mafalda Oliveira, Juan Miguel Cejalvo et al.|Nature Communications|2024Cited by 23
Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)Mafalda Oliveira, Aleix Prat, Tomás Pascual et al.|Clinical Cancer Research|2025Cited by 3